Maximum quantity allowed is 999
Please select the quantity
CAS RN: 599-79-1 | 제품번호: S0580
Sulfasalazine
×
![]()
×
순도/분석 방법: >95.0%(T)(HPLC)
동의어의:
- 5-[4-(2-Pyridylsulfamoyl)phenylazo]salicylic Acid
제품문서:
•본 제품의 재고는 일본 본사의 재고입니다. 주문시, 5일안에 실험실까지 도착됩니다.
•본건의 원가격은 한국 대리점의 예상 판매가격입니다.자세한 정보가 필요하시면 연락해 주십시오.( SEJIN CI Co., Ltd. (한국총대리점) 전화 : 02-2655-2480 이메일 : sales@sejinci.co.kr)
•보관 조건은 예고없이 변경 될 수 있습니다. 제품 보관 조건의 최신 자료는 홈페이지에 기재되어 있으니 양해 부탁드립니다.
•본건의 원가격은 한국 대리점의 예상 판매가격입니다.자세한 정보가 필요하시면 연락해 주십시오.( SEJIN CI Co., Ltd. (한국총대리점) 전화 : 02-2655-2480 이메일 : sales@sejinci.co.kr)
•보관 조건은 예고없이 변경 될 수 있습니다. 제품 보관 조건의 최신 자료는 홈페이지에 기재되어 있으니 양해 부탁드립니다.
| 제품번호 | S0580 |
Purity/Analysis Method 
|
>95.0%(T)(HPLC) |
| M.F. / M.W. | C__1__8H__1__4N__4O__5S = 398.39 |
| 물리적 상태 (20 ℃) | Solid |
| 보관 조건
|
Room Temperature (Recommended in a cool and dark place, <15°C) |
| 피해야 할 조건 | Light Sensitive |
| CAS RN | 599-79-1 |
| Reaxys-RN | 356241 |
| PubChem Substance ID | 87560165 |
| Merck Index (14) | 8942 |
| MDL 번호 | MFCD00057363 |
규격표
| Appearance | Light yellow to Amber to Dark green powder to crystal |
| Purity(HPLC) | min. 95.0 area% |
| Purity(Neutralization titration) | min. 95.0 % |
물성치(참고치)
| mp | 246 °C(dec.) |
| Solubility in water | Insoluble |
| 용해성 (미세 용접) | Alcohol |
| 용해도 (불용성) | Ether, Benzene, Chloroform |
GHS
| 픽토그램 |
|
| 신호 워드 | Warning |
| 위험물 및 유해 등록 | H351 : Suspected of causing cancer. |
| 주의 사항 | P501 : Dispose of contents/ container to an approved waste disposal plant. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P405 : Store locked up. |
법규 정보
| RTECS # | VO6250000 |
운송 정보
| HS 번호* | 2935.90-000 |
Application
Sulfasalazine: A Prodrug of 5-Aminosalicylic Acid (5-ASA), a NF-κB Inhibitor and an xCT Inhibitor
Sulfasalazine (salazosulfapyridin) is formed by combining sulfapyridine and salicylate with an azo bond. Sulfasalazine is split by intestinal bacteria to two main matabolites, sulfapyridine [S0071] and 5-aminosalicylic acid (5-ASA) [A0317], and the 5-ASA shows anti-inflammatory effects. Sulfasalazine is used as a gastrointestinal anti-inflammatory agent and is known as a potent inhibitor of NF-κB. Sulfasalazine is commonly used in the treatment of inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease (CD) and rheumatoid arthritis (RA).
Recently, the antitumor effects of sulfasalazine have attracted attention. CD44v is an adhesion molecule expressed in cancer stem-like cells. CD44v interacts with xCT, a glutamate-cysteine transporter, keeping high levels of the intracellular reduced glutathione (GSH) which an important antioxidant and stabilizer in cell. Sulfasalazine works as an xCT inhibitor, and suppresses CD44v-dependent tumor growth and increases sensitivity to cytotoxic drugs. (The product is for research purpose only.)
Recently, the antitumor effects of sulfasalazine have attracted attention. CD44v is an adhesion molecule expressed in cancer stem-like cells. CD44v interacts with xCT, a glutamate-cysteine transporter, keeping high levels of the intracellular reduced glutathione (GSH) which an important antioxidant and stabilizer in cell. Sulfasalazine works as an xCT inhibitor, and suppresses CD44v-dependent tumor growth and increases sensitivity to cytotoxic drugs. (The product is for research purpose only.)
References
- An experiment to determine the active therapeutic moiety of sulphasalazine
- Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazin
- The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites
- Salicylates for ulcerative colitis - their mode of action (a review)
- Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B
- Suppression of NF-κB activity by sulfasalazine is mediated by direct inhibition of IκB kinases α and β
- Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x-c cystine transporter: A new action for an old drug
- xCT Inhibition Depletes CD44v-Expressing Tumor Cells That Are Resistant to EGFR-Targeted Therapy in Head and Neck Squamous Cell Carcinoma
PubMed Literature
문서
제품문서 (분석 차트를 제공하지 못할 수도 있으니 양해 바랍니다.)
SDS
언어를 선택하십시오.
요청한 SDS를 사용할 수 없습니다.
번거롭게 해드려 죄송하지만 이 양식 보다 문의 해주십시오.
규격표
시험성적서， 각종 증명서
롯트 번호를 입력하십시오.
잘못된 로트 번호가 입력되었습니다.
샘플 시험성적서
시험성적서 샘플을 다운로드할 수 있습니다. 샘플은 반드시 최신 로트의 결과를 나타내는 것은 아닙니다.
본 제품의 샘플시험성적서는 현재 준비되어 있지 않습니다.
분석 차트
롯트 번호를 입력하십시오.
잘못된 로트 번호가 입력되었습니다.
죄송합니다만 찾으시는 분석차트는 없습니다.